Clinical Trials

Study Title:
A Randomized 3 Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR A) in Patients

For more information about the trial above please contact the study team:

Principal Investigator, Irl Greenwell, at greenwe@musc.edu, or please call +1 843-792-4759.

Study Coordinator, Christina Paskal, at paskal@musc.edu.

Trial opened at the following institutions: Medical University of South Carolina